Repository of Research and Investigative Information

Repository of Research and Investigative Information

Shoushtar Faculty of Medical Sciences

Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats

(2019) Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Biomedicine and Pharmacotherapy. pp. 530-535. ISSN 07533322 (ISSN)

[img] Text

Download (1MB)

Official URL:


Cardiotoxicity is an adverse effect of the anticancer drug doxorubicin (DOX). Gemfibrozil (GEM) is a lipid-lowering drug with a number of biological properties such as anti-inflammatory and antioxidant activities. Therefore, we decided to investigate the effect of GEM on DOX-induced cardiotoxicity in rats. Twenty-eight adult male Wistar rats were divided into four experimental groups as follows: Group I received normal saline (2 ml/kg) orally for 14 days, group II received DOX (2.5 mg/kg; in six injections; accumulative dose: 15 mg/kg) intraperitonially for 14 days, group III received DOX + GEM (100 mg/kg) orally for 14 days concomitantly with DOX administration, and group IV received GEM orally for 14 days. Lipid panel, various biochemical biomarkers, and histological observations were evaluated in serum and heart samples. According to our results, DOX significantly increased the levels of lipid panel (triglycerides, total cholesterol, and low-density lipoproteins cholesterol) as well as markers of cardiac dysfunction (Aspartate aminotransferase, Creatine kinase-muscle/brain, Lactate dehydrogenase and Cardiac Troponin I). Moreover, DOX significantly increased malondialdehyde and nitric oxide levels in cardiac tissue. Furthermore, administration of DOX reduced the level of glutathione as well as the superoxide dismutase, catalase, and Glutathione peroxidase activities. DOX-treated rats showed significantly higher tumor necrosis factor-α and interleukin-1β. GEM administration significantly attenuated the lipid panel and biochemical biomarkers in DOX-treated rats. Our results were confirmed by histopathological evaluations of the heart. Based on our findings, GEM is a promising cardioprotective agent in patients treated with DOX through mitigative effects on biochemical markers and oxidative stress indices. © 2018 Elsevier Masson SAS

Item Type: Article
Keywords: Cardioprotection Doxorubicin Gemfibrozil Rat
Divisions: Shoushtar Faculty of Medical Sciences > Department of Basic Science
Page Range: pp. 530-535
Journal or Publication Title: Biomedicine and Pharmacotherapy
Journal Index: Scopus
Volume: 109
Identification Number:
ISSN: 07533322 (ISSN)
Depositing User: خانم نجمه نوارباف

Actions (login required)

View Item View Item